However, the 15% pathological complete response rate in our study is within the mean pathological complete response rates of 9–33% from studies using resection material in patients with ER+/PR+/HER2- (range: 5.5–31.3%) and triple negative tumours (range: 20.3–62.2%) (Spring et al., 2020). Here, ERBB2 is linked to neoplasm.